JUNS on Nasdaq

JUPITER NEUROSCIENCES, INC.

American pharmaceutical preparations company based in Palm Beach Gardens. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Phio Pharmaceuticals Corp., SKINVISIBLE, INC. or BIOADAPTIVES, INC., or pick any stock.

TickerJUNS on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersJupiter, Florida¹
Incorporated inDE²
Business address1001 North Us Hwy 1, Suite 504, Jupiter, Fl 33477²
Filer category, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Nugevia PWR (“PWR”), which helps support mitochondrial function, which is a key for sustained growth and performance.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

80.6%Gross margin⁴

-40873.2%Operating margin⁴

-39662.8%Net margin⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentSelling, general and admin

Cost of revenue0¢$4.2K
Research and development23¢$2.1M
Selling, general and admin77¢$6.8M

Out of $21.8K in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁴$21.8K in 2025

Operating income⁵⁴-$8.9M in 2025+130% since 2023

Net income⁵⁴-$8.6M in 2025+81% since 2023

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Product Revenues, net	$21.8K	$0
Cost of goods sold	$4.2K
Gross Profit	$17.6K
Research and development	$2.1M	$492.7K
General and administrative	$6.8M	$2.6M
Total operating expenses	$8.9M	$3.1M
Operating loss	-$8.9M	-$3.1M
Interest income		$5.6K
Loss on change in fair value of derivative liability		-$53.3K
Gain on change in fair value of convertible notes	$281.9K
Interest expense	-$66.0K	-$248.4K
Gain on extinguishment of debt		$857.7K
Other income	$47.9K	$90.0K
Total other expenses, net	$263.8K	$651.7K
Net income (loss)	-$8.6M	-$2.4M
Basic	-$0.25	-$0.08
Diluted	-$0.25	-$0.08
Basic	34.6M shares	28.8M shares
Diluted	34.6M shares	28.8M shares

Total assets⁵⁴$5.6M in 2025+3645% since 2023

Total liabilities⁵⁴$7.4M in 2025+24% since 2023

Shareholders’ equity⁵⁴-$1.8M in 2025−74% since 2022

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2024-05-31	2023-12-31	2022-01-31
Cash	$3.8M	$3.8M
Account receivable	$2.6K
Prepaid contracts	$766.7K	$766.7K
Inventory, net	$159.8K
Other current assets	$106.5K	$114.1K
Total current assets	$4.8M	$4.7M
Operating lease right of use asset, net	$23.2K	$69.6K
Prepaid contracts, noncurrent	$712.1K	$1.5M
Other assets	$3.8K	$3.8K
Total assets	$5.6M	$6.2M
Accounts payable and accrued expenses	$638.6K	$396.5K
Accrued compensation	$1.4M	$1.4M
Accrued interest	$39.8K	$1.1K
Deferred revenue	$735
Current portion of operating lease liability	$21.2K	$50.1K
Convertible notes payable, fair value	$5.3M
Total current liabilities	$7.4M	$2.0M
Operating lease liability, net of current portion		$21.2K
Total liabilities	$7.4M	$2.0M
Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively	$3.4K	$3.3K
Additional paid in capital	$32.8M	$30.2M
Accumulated deficit	-$34.7M	-$26.0M
Total stockholders deficit	-$1.8M	$4.2M		-$5.8M
Total liabilities and stockholders deficit	$5.6M	$6.2M
Series A preferred stock, par value	$0.00	$0.00
Series A preferred stock, shares authorized	5.0M shares	5.0M shares
Common stock, par value	$0.00	$0.00	$0.00
Common stock, shares authorized	500.0M shares	125.0M shares	125.0M shares		45.0M shares
Common stock, share issued	34.4M shares	33.1M shares
Common stock, share outstanding	34.4M shares	33.1M shares

Period ending	2025-12-31	2024-12-31	2024-05-31	2023-12-31	2022-01-31
Cash	$3.8M	$3.8M
Account receivable	$2.6K
Prepaid contracts	$766.7K	$766.7K
Inventory, net	$159.8K
Other current assets	$106.5K	$114.1K
Total current assets	$4.8M	$4.7M
Operating lease right of use asset, net	$23.2K	$69.6K
Prepaid contracts, noncurrent	$712.1K	$1.5M
Other assets	$3.8K	$3.8K
Total assets	$5.6M	$6.2M
Accounts payable and accrued expenses	$638.6K	$396.5K
Accrued compensation	$1.4M	$1.4M
Accrued interest	$39.8K	$1.1K
Deferred revenue	$735
Current portion of operating lease liability	$21.2K	$50.1K
Convertible notes payable, fair value	$5.3M
Total current liabilities	$7.4M	$2.0M
Operating lease liability, net of current portion		$21.2K
Total liabilities	$7.4M	$2.0M
Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively	$3.4K	$3.3K
Additional paid in capital	$32.8M	$30.2M
Accumulated deficit	-$34.7M	-$26.0M
Total stockholders deficit	-$1.8M	$4.2M		-$5.8M
Total liabilities and stockholders deficit	$5.6M	$6.2M
Series A preferred stock, par value	$0.00	$0.00
Series A preferred stock, shares authorized	5.0M shares	5.0M shares
Common stock, par value	$0.00	$0.00	$0.00
Common stock, shares authorized	500.0M shares	125.0M shares	125.0M shares		45.0M shares
Common stock, share issued	34.4M shares	33.1M shares
Common stock, share outstanding	34.4M shares	33.1M shares

Cash from operations⁵⁴-$5.4M in 2025+1026% since 2023

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net Loss	-$8.6M	-$2.4M
Loss on change in fair value of derivative liability		$53.3K
Gain on change in fair value of convertible notes	-$281.9K
Amortization of debt discounts		$43.3K
Loss (Gain) on extinguishment of debt		-$857.7K
Gain on forgiveness of accrued compensation		-$40.0K
Amortization of prepaid contracts	$766.7K	$54.6K
Non-cash financing cost	$200.0K
Interest expense paid through sale of common stock	$22.5K
Stock-based compensation	$2.4M	$1.8M
Increase in accounts receivable	-$2.6K
Decrease (increase) in prepaid contracts		-$2.3M
Increase in prepaid and other current assets		-$113.8K
Increase in inventory	-$159.8K
Increase in other current assets	$7.5K
Decrease in operating lease right of use asset	-$3.7K	-$1.8K
Increase in deferred revenue	$735
Increase in accounts payable and accrued expenses	$242.2K	-$149.5K
Decrease in accrued compensation	-$17.7K	-$46.9K
Increase in accrued interest	$38.8K	$46.4K
Net cash used in operating activities	-$5.4M	-$3.9M
Proceeds from note payable, related parties		$138.5K
Payment on convertible note payable		-$150.0K
Proceeds from issuance convertible note payable, net	$5.6M
Proceeds from offering, net of offering costs		$9.7M
Proceeds from sale of common stock		$150.0K
Net cash provided by financing activities	$5.4M	$7.7M
Net Change in Cash	$19.8K	$3.7M
Cash paid for interest	$38.4K	$147.8K
Restricted stock issued for forgiveness of salary		$10.0K
Stock options issued for forgiveness of salary		$50.0K
Notes payable, related party assign to Note payable		$266.7K
Stock issued in connection with convertible promissory notes	$200.0K	$636.9K
Stock issued in connection interest payment	$22.5K

Compare JUPITER NEUROSCIENCES, INC. with another company

Leadership

Who has led JUPITER NEUROSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerChrister Rosen Nov 8, 2024 to now⁸
ChairChrister Rosen Nov 8, 2024 to now⁸
PresidentAlison D. Silva Jun 4, 2026 to now⁹
Chief financial officerSaleem Elmasri Nov 8, 2024 to now¹⁰
Chief operating officerAlison D. Silva Jun 4, 2026 to now⁹

Board members and other officers (11)

Chief Administrative OfficerAlexander Gustaf Erik Rosen Nov 8, 2024 to now¹¹
Pres + Chief Business OfficerAlison D. Silva Nov 8, 2024 to now¹²
Chief Scientific OfficerMarshall A. Hayward Nov 8, 2024 to now¹³
Board memberTomas Jan Philipson Jul 1, 2026 to now¹⁴
Board memberAndrew Jon Cutler Jul 22, 2026 to now¹⁵
Board memberAlison D. Silva Nov 8, 2024 to now¹²
Board memberAllison W. Brady Nov 8, 2024 to now¹⁶
Board memberHolger Weis Nov 8, 2024 to now¹⁷
Board memberJulie B. Kampf Nov 8, 2024 to now¹⁸
Board memberMarshall A. Hayward Nov 8, 2024 to now¹³
Board memberNicholas H. Hemmerly Nov 8, 2024 to now¹⁹

Named in SEC Form D filings

People the company listed in its private-offering notices.

DirectorHolger Weiss named Sep 4, 2026²⁰

Former names

Jupiter Orphan Therapeutics, Inc.Jul 15, 2016 to Dec 5, 2017²

Timeline

Nov 8, 2024New chief executive Christer Rosen becomes CEO⁸

Filings

199 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 28 major events, 36 insider forms, 8 large holders, 1 private raises, 118 other. The latest 20:

Oct 13, 2026S-8 EDGAR
Sep 25, 2026S-3 EDGAR
Sep 22, 2026SCHEDULE 13G EDGAR
Sep 4, 2026D EDGAR
Sep 3, 20268-K EDGAR
Aug 28, 2026SCHEDULE 13G/A EDGAR
Aug 28, 2026SCHEDULE 13G EDGAR
Aug 28, 20268-K EDGAR
Aug 27, 20268-K EDGAR
Aug 24, 20268-K EDGAR
Aug 24, 20268-K EDGAR
Aug 24, 2026424B5 EDGAR
Aug 14, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Aug 5, 20264 EDGAR
Jul 29, 2026424B3 EDGAR
Jul 28, 20268-K EDGAR
Jul 27, 2026424B3 EDGAR
Jul 27, 20268-K EDGAR
Jul 22, 20263 EDGAR

The 199 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jul 1, 2025	Silva Alison D.President and COO	Buy	750	$1.03	$772	Form 4
Jul 1, 2025	ROSEN CHRISTERCEO and Chairman	Buy	3,600	$1.02	$3.7K	Form 4
Jun 30, 2025	Silva Alison D.President and COO	Buy	950	$1.03	$980	Form 4
Jun 30, 2025	ROSEN CHRISTERCEO and Chairman	Buy	7,650	$1.02	$7.8K	Form 4
Jun 27, 2025	Silva Alison D.President and COO	Buy	850	$1.03	$876	Form 4
Jun 27, 2025	ROSEN CHRISTERCEO and Chairman	Buy	166	$1.06	$176	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

PharmAla Biotech Holdings Inc.SCHEDULE 13G, 1 filing Sep 22, 2026²¹
Orca Capital AGSCHEDULE 13G/A, 2 filings Aug 28, 2026²²
Alexander Gustaf Erik RosenSC 13D, 1 filing Nov 15, 2024²³
Christer RosenSC 13D, 1 filing Nov 15, 2024²⁴
Claes Robert WahlestedtSC 13D, 1 filing Nov 15, 2024²⁵
Marshall A. HaywardSC 13D, 1 filing Nov 15, 2024²⁶
Shaun Paul BrothersSC 13D, 1 filing Nov 15, 2024²⁷

Money raised

Private offerings the company reported to the SEC on Form D.

Aug 20, 2026Raised $774,787 in a private offering of equity Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARJUPITER NEUROSCIENCES, INC. filings on SEC EDGAR
2
SEC EDGARJUPITER NEUROSCIENCES, INC. filings on SEC EDGAR
3
SEC EDGARJUPITER NEUROSCIENCES, INC. annual report, Item 1 (Business)
4
SEC EDGARJUPITER NEUROSCIENCES, INC. 10-K for fiscal 2025
5
SEC EDGARJUPITER NEUROSCIENCES, INC. 10-K for fiscal 2023
6
SEC EDGARJUPITER NEUROSCIENCES, INC. 10-Q for fiscal 2026
7
SEC EDGARJUPITER NEUROSCIENCES, INC. 10-Q for fiscal 2026
8
SEC EDGARChrister Rosen, Chief executive officer
9
SEC EDGARAlison D. Silva, President
10
SEC EDGARSaleem Elmasri, Chief financial officer
11
SEC EDGARAlexander Gustaf Erik Rosen, Chief Administrative Officer
12
SEC EDGARAlison D. Silva, Pres + Chief Business Officer
13
SEC EDGARMarshall A. Hayward, Chief Scientific Officer
14
SEC EDGARTomas Jan Philipson, Board member
15
SEC EDGARAndrew Jon Cutler, Board member
16
SEC EDGARAllison W. Brady, Board member
17
SEC EDGARHolger Weis, Board member
18
SEC EDGARJulie B. Kampf, Board member
19
SEC EDGARNicholas H. Hemmerly, Board member
20
SEC EDGARJUPITER NEUROSCIENCES, INC. Form D naming Holger Weiss
21
SEC EDGARPharmAla Biotech Holdings Inc. SCHEDULE 13G on JUPITER NEUROSCIENCES, INC.
22
SEC EDGAROrca Capital AG SCHEDULE 13G/A on JUPITER NEUROSCIENCES, INC.
23
SEC EDGARAlexander Gustaf Erik Rosen SC 13D on JUPITER NEUROSCIENCES, INC.
24
SEC EDGARChrister Rosen SC 13D on JUPITER NEUROSCIENCES, INC.
25
SEC EDGARClaes Robert Wahlestedt SC 13D on JUPITER NEUROSCIENCES, INC.
26
SEC EDGARMarshall A. Hayward SC 13D on JUPITER NEUROSCIENCES, INC.
27
SEC EDGARShaun Paul Brothers SC 13D on JUPITER NEUROSCIENCES, INC.